Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) has received an average recommendation of “Hold” from the twelve analysts that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $13.50.

ZYNE has been the topic of several research reports. Zacks Investment Research raised Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 10th. ValuEngine raised Zynerba Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Oppenheimer reissued a “hold” rating on shares of Zynerba Pharmaceuticals in a research report on Tuesday, November 14th. Cantor Fitzgerald set a $17.00 target price on Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, November 20th. Finally, Roth Capital cut Zynerba Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $30.00 to $7.00 in a research report on Tuesday, August 8th.

In related news, major shareholder Michael Rapp acquired 44,255 shares of the stock in a transaction dated Thursday, October 19th. The shares were purchased at an average cost of $9.59 per share, with a total value of $424,405.45. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 9.91% of the company’s stock.

Hedge funds have recently bought and sold shares of the company. Nationwide Fund Advisors purchased a new position in shares of Zynerba Pharmaceuticals during the 2nd quarter valued at about $110,000. The Manufacturers Life Insurance Company purchased a new position in shares of Zynerba Pharmaceuticals during the 2nd quarter valued at about $158,000. Bank of New York Mellon Corp lifted its position in shares of Zynerba Pharmaceuticals by 5.5% during the 1st quarter. Bank of New York Mellon Corp now owns 12,165 shares of the company’s stock valued at $245,000 after buying an additional 635 shares in the last quarter. New York State Common Retirement Fund purchased a new position in shares of Zynerba Pharmaceuticals during the 2nd quarter valued at about $207,000. Finally, Parametric Portfolio Associates LLC purchased a new position in shares of Zynerba Pharmaceuticals during the 2nd quarter valued at about $223,000. 27.03% of the stock is currently owned by hedge funds and other institutional investors.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) traded up $0.81 during trading on Thursday, hitting $14.58. The company had a trading volume of 491,309 shares, compared to its average volume of 524,282. Zynerba Pharmaceuticals has a 12 month low of $5.42 and a 12 month high of $25.95.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last released its quarterly earnings data on Tuesday, November 14th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.05). During the same quarter in the prior year, the firm earned ($0.67) earnings per share. research analysts predict that Zynerba Pharmaceuticals will post -2.49 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Analysts Set Zynerba Pharmaceuticals, Inc. (ZYNE) Price Target at $13.50” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/03/analysts-set-zynerba-pharmaceuticals-inc-zyne-price-target-at-13-50.html.

Zynerba Pharmaceuticals Company Profile

Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

Analyst Recommendations for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Stock Ratings for Zynerba Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.